In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Silicon Genetics

Division of Agilent Technologies Inc.

Latest From Silicon Genetics

Recent Dealmaking (9/2003)

Summarizing the month in European dealmaking.

Of Mice and Men: Predictive Toxicology

Current in vivo and in vitro models can't keep up with the demand for the safety assessment of large numbers of compounds emerging from high-throughput strategies. Pharmaceutical companies and start-ups are therefore building new systems that they hope will be capable of predicting the toxicity liabilities of new compounds. Cheminformatics can help week out toxic compounds at the lead selection and optimization stage; toxicogenomics may provide a toxicity diagnostic capability at all stages of drug development. For both toxicology approaches, there is not yet enough high quality data to build predictive models. Toxicology-focused cheminformatics programs attempt to consolidate data from hitherto untapped sources; toxicogenomics companies are engaged in the fussy and expensive process of manufacturing data from scratch and validating them with biological experiments.

Clinical Trials Regulation

Silicon Genetics

Now that there is a growing number of labs producing gene expression data, researchers find themselves in need of better software tools to make sense of the data. So Silicon Genetics came out with {GeneSpring}, to allow complex comparisons among genes, allowing scientists to figure out, for example, what genes behave in similar ways.

BioPharmaceutical Research and Development Strategies

Data Mining

Data mining is the neologism given to the tools of pattern recognition and discovery, themselves a grab bag of mathematical methods used to glean information from complex or noisy data sets. If the number of start-ups like Silicon Genetics is any measure, the pharmaceutical industry looks like data mining's next big market.

BioPharmaceutical Platform Technologies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Agilent Technologies Inc.
  • Senior Management
  • Saeid Akhtari, Pres. & CEO
    Michael Bates, CFO
    Kevin Wandryk, VP, Mktg. & Bus. Dev.
    Gregory Kinch, VP, Sales & Services
  • Contact Info
  • Silicon Genetics
    Phone: (650) 367-9600
    2601 Spring St.
    Redwood City, CA 94063